CoChat

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Turner, Erick H · 2019 · The Lancet Psychiatry

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30394-3

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 4 references

Cited by

See all 174

Metadata

Authors
Turner, E. H.
Affiliations
Oregon Health & Science University (US)
Corresponding author
Turner, Erick H
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2019-12
Volume
6
Issue
12
Pages
977-979
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2982569821
Cited by
156
References
4
Citations by year
2026: 12 · 2025: 15 · 2024: 28 · 2023: 22 · 2022: 26 · 2021: 22 · 2020: 30 · 2019: 1
FWCI
12.31
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Psychiatry (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
esketamine, treatment-resistant depression, FDA drug approval, antidepressant efficacy, antidepressant safety, NMDA receptor antagonists, ketamine, brexanolone, postpartum depression, risk-benefit assessment, breakthrough therapy designation, mental health services funding, mental health professionals
MeSH terms
Clinical Trials as Topic, Humans, Ketamine, United States, United States Food and Drug Administration, Treatment Outcome, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30394-3
The paper
Turner, E. H. (2019). Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30394-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.